Lonza Group (LZAGY) Stock Price, News & Analysis

Company Overview

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza's client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services. Lonza also supplies a range of life science products such as cell culture media, reagents and tools used in research and development, as well as active pharmaceutical ingredients (APIs), excipients and formulation services. In recent years it has expanded capabilities in advanced therapies, including cell and gene therapy support, viral vector production and related upstream and downstream processing services.

Lonza emphasizes integrated partnerships that span early-stage development through commercial manufacturing, regulatory support and quality assurance to help clients accelerate time to market. Its operations typically combine technical development teams, GMP manufacturing suites and analytical laboratories to provide scalable solutions tailored to client programs. The company’s offerings are positioned to address growing demand for outsourced biomanufacturing, biologics and advanced-therapy production capacity worldwide.

Originally established in Switzerland, Lonza has grown through organic investment and strategic acquisitions to build an international footprint and diversified service portfolio. The company is governed by an executive management team and a board based in Switzerland and operates under global regulatory standards applicable to pharmaceutical and biotech manufacturing. Lonza’s broad service scope and global infrastructure make it a significant contract partner for companies seeking outsourced development and manufacturing expertise in the life sciences sector.

Key Stats

• Today's Range: $59.27 to $59.80
• 50-Day Range: $58.78 to $69.27
• 52-Week Range: $58.53 to $73.85
• Volume: 116,004 shs
• Average Volume: 72,297 shs
• Market Capitalization: $41.79 billion
• P/E Ratio: N/A
• Dividend Yield: 0.24%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Lonza Group Stock Analysis - MarketRank™

Lonza Group scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Lonza Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Lonza Group has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 22.77%

Earnings Growth

Earnings for Lonza Group are expected to grow by 22.77% in the coming year, from $2.24 to $2.75 per share.

Price to Earnings Growth Ratio

Lonza Group has a PEG Ratio of 1.16. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Lonza Group has a P/B Ratio of 3.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Lonza Group has been sold short.

Short Interest Ratio / Days to Cover

Lonza Group has a short interest ratio ("days to cover") of 0.23, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lonza Group has recently increased by 117.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Lonza Group has a dividend yield of 0.24%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Lonza Group does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Lonza Group will have a dividend payout ratio of 5.09% next year. This indicates that Lonza Group will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: -0.50

News Sentiment

Lonza Group has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Lonza Group this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lonza Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.07% of the stock of Lonza Group is held by insiders.

Percentage Held by Institutions

0.04% of the stock of Lonza Group is held by institutions.

Company Calendar

• Today: 5/17/2026
• Next Earnings (Estimated): 7/22/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LZAGY
• CIK: 1446711
• Web: www.lonza.com
• Phone: (161) 316-8111
• Fax: 41-61-316-9111
• Employees: 18,686
• Year Founded: 1897

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 26.57
• P/E Growth: 1.16
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.42
• Current Ratio: 2.24
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: $7.88 billion
• Price / Sales: 5.30
• Cash Flow: $1.99 per share
• Price / Cash Flow: 29.95
• Book Value: $15.79 per share
• Price / Book: 3.77

Miscellaneous

• Outstanding Shares: 702,290,000
• Free Float: 701,798,000
• Market Cap: $41.79 billion
• Optionable: Not Optionable
• Beta: 1.14